Name | 9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one |
---|---|
Synonyms | as-35 |
Description | AS-35 is an orally effective, potent and selective antagonist of leukotrienes, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC50 values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities. |
---|---|
Related Catalog | |
Target |
LTE4:3 nM (IC50, In isolated guinea pig ileum) LTD4:4 nM (IC50, In isolated guinea pig ileum) LTC4:8 nM (IC50, In isolated guinea pig ileum) |
In Vitro | In isolated guinea pig preparations, AS-35 antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC50 values of 8 nM, 4 nM and 3 nM, respectively. In the trachea, the agent also antagonizes LTD4 and LTE4-induced con tractions with IC50 values of 10 nM and 20 nM, respectively. However, AS-35 does not antagonize LTC4-induced tracheal contraction in the presence of L-serine borate[1]. |
In Vivo | AS-35 (0.0375 to 0.3 mg/kg, i.v.) dose-dependently antagonizes bronchoconstriction induced by i.v.-injection of LTC4 and LTD4 in anesthetized guinea pigs, but does not inhibit histamine-induced bronchoconstriction. Oral administration of AS-35 also antagonizes LTD4 as well as antigen-induced LT-mediated bronchoconstriction. AS-35 (p.o.) inhibits LTD4-induced increase in the cutaneous vascular permeability of guinea pig[1]. |
References |
Density | 1.46g/cm3 |
---|---|
Boiling Point | 678.8ºC at 760mmHg |
Molecular Formula | C21H20N6O4 |
Molecular Weight | 420.42100 |
Flash Point | 364.4ºC |
Exact Mass | 420.15500 |
PSA | 135.36000 |
LogP | 2.31430 |
Vapour Pressure | 4.74E-19mmHg at 25°C |
Index of Refraction | 1.707 |
Storage condition | 2-8℃ |
~98% 108427-72-1 |
Literature: Tokyo Tanabe Co. Ltd. Patent: US4816459 A1, 1989 ; |
~65% 108427-72-1 |
Literature: Tokyo Tanabe Co. Ltd. Patent: US4816459 A1, 1989 ; |
Precursor 2 | |
---|---|
DownStream 0 |